Key facts
- Craniometrix’s last known valuation is $62.0M (Feb 2026).
- It has raised $21.5M; the latest was Later Stage VC ($15.0M) in Feb 2026.
- Notable investors include Y Combinator, Rebel Fund, Quiet Capital, Olive Tree Capital, Defy Partners Management — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Craniometrix
- ·The full record, as it builds
Funding rounds
No funding rounds for Craniometrix are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Craniometrix
Developer of an AI-enabled dementia care navigation platform designed to help healthcare providers implement and manage comprehensive dementia care programs. The company's platform offers AI-powered care coordination software, comprehensive assessments, care planning tools, continuous monitoring, and collaboration with trained social workers and clinicians, enabling healthcare providers to manage dementia patients between visits while meeting regulatory requirements and maintaining clinical oversight.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2014
- Employees
- 26
- Website
- craniometrix.com/
- Ownership
- Privately Held (backing)
Craniometrix doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Craniometrix shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Craniometrix in its N-PORT filings yet. We sweep new filings monthly.